US20180291032A1 - Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations - Google Patents

Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations Download PDF

Info

Publication number
US20180291032A1
US20180291032A1 US15/811,536 US201715811536A US2018291032A1 US 20180291032 A1 US20180291032 A1 US 20180291032A1 US 201715811536 A US201715811536 A US 201715811536A US 2018291032 A1 US2018291032 A1 US 2018291032A1
Authority
US
United States
Prior art keywords
rifaximin
polymorphic form
diffraction pattern
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/811,536
Inventor
Giuseppe Claudio Viscomi
Manuela Campana
Donatella Confortini
Maria Barbanti
Dario Braga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfasigma SpA
Original Assignee
Alfasigma SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34934045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20180291032(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfasigma SpA filed Critical Alfasigma SpA
Priority to US15/811,536 priority Critical patent/US20180291032A1/en
Assigned to ALFA WASSERMANN S.P.A. reassignment ALFA WASSERMANN S.P.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BARBANTI, MARIA MIRIAM, BRAGA, DARIO, CAMPANA, MANUELA, CONFORTINI, DONATELLA, VISCOMI, GIUSEPPE CLAUDIO
Assigned to ALFASIGMA S.P.A. reassignment ALFASIGMA S.P.A. MERGER (SEE DOCUMENT FOR DETAILS). Assignors: ALFA WASSERMANN S.P.A.
Publication of US20180291032A1 publication Critical patent/US20180291032A1/en
Priority to US16/291,900 priority patent/US10703763B2/en
Priority to US16/878,511 priority patent/US20200277301A1/en
Priority to US17/563,579 priority patent/US20220119403A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D499/00Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/21Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D499/44Compounds with an amino radical acylated by carboxylic acids, attached in position 6
    • C07D499/48Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical
    • C07D499/58Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical
    • C07D499/64Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Definitions

  • the rifaximin (INN; see The Merck Index, XIII Ed., 8304) is an antibiotic pertaining to the rifamycin class, exactly it is a pyrido-imidazo rifamycin described and claimed in the Italian Patent IT 1154655, while the European Patent EP 0161534 describes and claims a process for its production starting from the rifamycin O (The Merck Index, XIII Ed., 8301).
  • the polymorphous forms of the rifaximin have been characterized through the technique of the powder X-ray diffraction.
  • the form ⁇ is characterized by the residual content of water in the dried solid material in the range from 2.5% and 6% (w/w), more preferably from 3% and 4.5%, while the form ⁇ is the result of a polymorphic transition under controlled temperature moving from the form ⁇ .
  • Rifaximin exerts its broad antibacterial activity in the gastrointestinal tract against localized gastrointestinal bacteria that cause infectious diarrhea including anaerobic strains. It has been reported that rifaximin is characterized by a negligible systemic absorption, due to its chemical and physical characteristics (Descombe J. J. et al. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin. Pharmacol. Res., 14 (2), 51-56, (1994))
  • the evidenced difference in the bioavailability is important because it can differentiate the pharmacological and toxicological behavior of the two polymorphous of rifaximins ⁇ and ⁇ .
  • rifaximin ⁇ is negligibly absorbed through the oral route while rifaximin ⁇ shows a mild absorption.
  • Rifaximin ⁇ is practically not absorbed, might act only through a topical action, including the case of the gastro-intestinal tract, with the advantage of very low toxicity.
  • rifaximin ⁇ which is mildly absorbed, can find an advantageous use against systemic microorganisms, able to hide themselves and to partially elude the action of the topic antibiotics.
  • rifaximin belongs to the rifamycin family, a member of which, the rifampicin, is largely used in tuberculosis therapy.
  • the current short course treatment of tuberculosis is a combination therapy involving four active pharmaceutical ingredients: rifampicin, isoniazid, ethambutol and pyrazinamide and among them rifampicin plays a pivotal role. Therefore, any drug which jeopardized the efficacy of the therapy by selecting for resistance to rifampicin would be harmful.
  • the process for manufacturing rifaximin from rifamycin O disclosed and claimed in EP 0161534 is deficient from the point of view of the purification and identification of the product obtained; it shows some limits also from the synthetic point of view as regards, for instance, the very long reaction times, from 16 to 72 hours, very little suitable for an industrial use and moreover because it does not provide for the in situ reduction of the rifaximin oxidized that may be formed within the reaction mixture.
  • a further object of the present invention is an improved process for the industrial manufacturing of the ⁇ and ⁇ forms of the rifaximin, herein claimed as products and usable as defined and homogeneous active principles in the manufacture of the medicinal preparations containing such active principle.
  • FIG. 1 is a powder X-ray diffractogram of rifaximin ⁇ .
  • FIG. 2 is a powder X-ray diffractogram of rifaximin ⁇ .
  • the form ⁇ and the form c of the antibiotic known as rifaximin (INN), processes for their production and the use thereof in the manufacture of medicinal preparations for oral or topical route, are object of the present invention.
  • a process object of the present invention comprises reacting one molar equivalent of rifamycin O with an excess of 2-amino-4-methylpyridine, preferably from 2.0 to 3.5 molar equivalents, in a solvent mixture made of water and ethyl alcohol in volumetric ratios between 1:1 and 2:1, for a period of time between 2 and 8 hours at a temperature between 40° C. and 60° C.
  • the reaction mass is cooled to room temperature and is added with a solution of ascorbic acid in a mixture of water, ethyl alcohol and aqueous concentrated hydrochloric acid, under strong stirring, in order to reduce the small amount of oxidized rifaximin that forms during the reaction and finally the pH is brought to about 2.0 by means of a further addition of concentrated aqueous solution of hydrochloric acid, in order to better remove the excess of 2-amino-4-methylpyridine used in the reaction.
  • the suspension is filtered and the obtained solid is washed with the same solvent mixture water/ethyl alcohol used in the reaction.
  • Such semi finished product is called “raw rifaximin”.
  • the raw rifaximin can be directly submitted to the subsequent step of purification.
  • the raw rifaximin can be dried under vacuum at a temperature lower than 65° C. for a period of time between 6 and 24 hours, such semi finished product is called “dried raw rifaximin”.
  • the so obtained raw rifaximin and/or dried raw rifaximin are purified by dissolving them in ethyl alcohol at a temperature between 45° C. and 65° C. and by crystallizing them by addition of water, preferably in weight amounts between 15% and 70% in respect of the amount by weight of the ethyl alcohol used for the dissolution, and by keeping the obtained suspension at a temperature between 50° C. and 0° C. under stirring during a period of time between 4 and 36 hours.
  • the suspension is filtered and the obtained solid is washed with water and dried under vacuum or under normal pressure, with or without a drying agent, at a temperature between the room temperature and 105° C. for a period of time between 2 and 72 hours.
  • the achievement of the ⁇ and ⁇ forms depends on the conditions chosen for the crystallization.
  • the composition of the solvent mixture from which the crystallization is carried out, the temperature at which the reaction mixture is kept after the crystallization and the period of time at which that temperature is kept have proven to be critical.
  • the ⁇ and ⁇ rifaximins are obtained when the temperature is first brought to a value between 28° C. and 32° C. in order to cause the beginning of the crystallization, then the suspension is brought to a temperature between 40° C. and 50° C. and kept at this value for a period of time between 6 and 24 hours, then the suspension is quickly cooled to 0° C., in a period of time between 15 minutes and one hour, is filtered, the solid is washed with water and then is dried.
  • the step of drying has an important part in obtaining the ⁇ and ⁇ polymorphous forms of the rifaximin and has to be checked by means of a suitable method fit for the water dosage, like for instance the Karl Fisher method, in order to check the amount of remaining water present in the product under drying.
  • the obtaining of the rifaximin ⁇ during the drying in fact depends on the end remaining amount of water which should be comprised from 2.5% (w/w) and 6% (w/w), more preferably between—3% and 4.5%, and not from the experimental conditions of pressure and temperature at which this critical limit of water percent is achieved.
  • Both the forms ⁇ and ⁇ of the rifaximin are hygroscopic, they absorb water in a reversible way during the time in the presence of suitable conditions of pressure and humidity in the ambient and are susceptible of transformation to other forms.
  • the process concerning the transformation of the rifaximin ⁇ into rifaximin E comprises drying the rifaximin ⁇ under vacuum or at atmospheric pressure, at room temperature or at high temperatures, in the presence or in the absence of drying agents, and keeping it for a period of time until the conversion is obtained, usually between 6 and 36 hours.
  • the polymorph called rifaximin ⁇ is characterized from a content of water in the range between 2.5% and 6%, preferably between 3.0% and 4.5% and from a powder X-ray diffractogram (reported in FIG. 1 ) which shows peaks at the values of the diffraction angles 2 ⁇ of 5.70° ⁇ 0.2, 6.7° ⁇ 0.2, 7.1° ⁇ 0.2, 8.0° ⁇ 0.2, 8.7° ⁇ 0.2, 10.4° ⁇ 0.2, 10.8° ⁇ 0.2, 11.3° ⁇ 0.2, 12.1° ⁇ 0.2, 17.0° ⁇ 0.2, 17.3° ⁇ 0.2, 17.5° ⁇ 0.2, 18.5° ⁇ 0.2, 18.8° ⁇ 0.2, 19.1° ⁇ 0.2, 21.0° ⁇ 0.2, 21.5° ⁇ 0.2.
  • the polymorph called rifaximin E is characterized from a powder X-ray diffractogram (reported in FIG. 2 ) which shows peaks at the values of the diffraction angles 2 ⁇ of 7.0° ⁇ 0.2, 7.3° ⁇ 0.2, 8.2° ⁇ 0.2, 8.7° ⁇ 0.2, 10.3° ⁇ 0.2, 11.1° ⁇ 0.2, 11.7° ⁇ 0.2, 12.4° ⁇ 0.2, 14.5° ⁇ 0.2, 16.3° ⁇ 0.2, 17.2° ⁇ 0.2, 18.0° ⁇ 0.2, 19.4° ⁇ 0.2.
  • the diffractograms have been carried out by means of the Philips X'Pert instrument endowed with Bragg-Brentano geometry and under the following working conditions:
  • Rifaximin ⁇ and rifaximin ⁇ differ each from other also because they show significant differences as regards bioavailability.
  • Beagle female dogs treated them by oral route with a dose of 100 mg/kg in capsule of one of the polymorphs, collecting blood samples from the jugular vein of each animal before each dosing and 1, 2, 4, 6, 8 and 24 hours after each dosing, transferring the samples into tubes containing heparin and separating the plasma by centrifugation.
  • the plasma has been assayed for rifaximin on the validated LC-MS/MS method and the maximum observed plasma concentration (Cmax), the time to reach the Cmax (Tmax), and the area under the concentration-time curve (AUC) have been calculated.
  • the forms ⁇ and ⁇ can be advantageously used in the production of medicinal preparations having antibiotic activity, containing rifaximin, for both oral and topical use.
  • the medicinal preparations for oral use contain the rifaximin ⁇ and a together with the usual excipients as diluting agents like mannitol, lactose and sorbitol; binding agents like starches, gelatins, sugars, cellulose derivatives, natural gums and polyvinylpyrrolidone; lubricating agents like talc, stearates, hydrogenated vegetable oils, polyethylenglycol and colloidal silicon dioxide: disintegrating agents like starches, celluloses, alginates, gums and reticulated polymers; coloring, flavoring and sweetening agents.
  • All the solid preparations administrable by oral route can be used in the ambit of the present invention, for instance coated and uncoated tablets, capsules made of soft and hard gelatin, sugar-coated pills, lozenges, wafer sheets, pellets and powders in sealed packets.
  • the medicinal preparations for topical use contain the rifaximin ⁇ and ⁇ together with the usual excipients like white petrolatum, white wax, lanoline and derivatives thereof, stearylic alcohol, propylenglycol, sodium lauryl sulfate, ethers of the fatty polyoxyethylene alcohols, esters of the fatty polyoxyethylene acids, sorbitan monostearate, glyceryl monostearate, propylene glycol monostearate, polyethylene glycols, methylcellulose, hydroxymethylpropylcellulose, sodium carboxymethylcellulose, colloidal aluminum and magnesium silicate, sodium alginate.
  • the usual excipients like white petrolatum, white wax, lanoline and derivatives thereof, stearylic alcohol, propylenglycol, sodium lauryl sulfate, ethers of the fatty polyoxyethylene alcohols, esters of the fatty polyoxyethylene acids, sorbitan monostearate, glyceryl monostearate, propylene
  • All the topical preparations can be used in the ambit of the present invention, for instance the ointments, the pomades, the creams, the gels and the lotions.
  • the mass is kept under stirring, always at an interior temperature equal to 20° C., for 30 minutes, then the precipitate is filtered and washed by means of a mixture made of 32 ml of demineralized water and of 25 ml of ethyl alcohol.
  • the so obtained “raw rifaximin” (89.2 g) is dried under vacuum at room temperature for 12 hours obtaining 64.4 g of “dried raw rifaximin” which shows a water content equal to 5.6%.
  • the product by further drying under vacuum until the weight of 62.2 g of dried raw rifaximin having a water content equal to 3.3%, whose diffractogram corresponds to the polymorphous form ⁇ characterized from a powder X-ray diffractogram showing peaks at values of angles 2 ⁇ of 5.7° ⁇ 0.2, 6.7° ⁇ 0.2, 7.1° ⁇ 0.2, 8.0°:0.2, 8.7° ⁇ 0.2, 10.4° ⁇ 0.2, 10.8° ⁇ 0.2, 11.3° ⁇ 0.2, 12.1° ⁇ 0.2, 17.0° ⁇ 0.2, 17.3° ⁇ 0.2, 17.5° ⁇ 0.2, 18.5° ⁇ 0.2, 18.8° ⁇ 0.2, 19.1° ⁇ 0.2, 21.0° ⁇ 0.2, 21.5° ⁇ 0.2.
  • the product is hygroscopic.
  • Example 1 is repeated and after having obtained the 6 form, the solid powder is further dried under vacuum for 24 hours at the temperature of 65° C.
  • the product obtained is rifaximin ⁇ characterized from a powder X-ray diffractogram showing peaks at values of angles 2 ⁇ of 7.0° ⁇ 0.2, 7.3° ⁇ 0.2, 8.2° ⁇ 0.2, 8.7010.2, 10.3° ⁇ 0.2, 11.1° ⁇ 0.2, 11.7° ⁇ 0.2, 12.4° ⁇ 0.2, 14.5° ⁇ 0.2, 16.3° ⁇ 0.2, 17.2° ⁇ 0.2, 18.0° ⁇ 0.2, 19.4° ⁇ 0.2.
  • the first of these group has been treated with rifaximin ⁇ , the second with rifaximin ⁇ according to the following procedure.
  • Each sample has been transferred into a tube containing heparin as anticoagulant and has been centrifuged; the plasma has been divided into two aliquots, each of 500 ⁇ l, and has been frozen at ⁇ 20° C.
  • the rifaximin contained in the plasma has been assayed by means of the validated LC-MS/MS method and the following parameters have been calculated according to standard non-compartmental analysis:
  • Cmax maximum observed plasma concentration of rifaximin in the plasma
  • Tmax time at which the Cmax is reached
  • AUC area under the concentration-time curve calculated through the linear trapezoidal rule.

Abstract

Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin δ and rifaximin ε useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

Description

    RELATED APPLICATIONS
  • The present application is a continuation under 35 U.S.C § 120 of U.S. patent application Ser. No. 13/488,345, filed Jun. 4, 2012, which is a continuation of U.S. patent application Ser. No. 11/658,702, filed Oct. 8, 2007, now U.S. Pat. No. 8,193,196. issued on Jun. 5, 2012, which in turn is filed under 35 U.S.C. § 371 as the U.S. national application of International Patent Application No. PCT/EP2006/001755, filed Feb. 27, 2006, which in turn claims priority to the European Patent Application No. EP 05004695.2, filed Mar. 3, 2005, the entire disclosure of all of which is hereby incorporated by reference herein, including the drawings.
  • BACKGROUND OF THE INVENTION
  • The rifaximin (INN; see The Merck Index, XIII Ed., 8304) is an antibiotic pertaining to the rifamycin class, exactly it is a pyrido-imidazo rifamycin described and claimed in the Italian Patent IT 1154655, while the European Patent EP 0161534 describes and claims a process for its production starting from the rifamycin O (The Merck Index, XIII Ed., 8301).
  • Both these patents describe the purification of the rifaximin in a generic way saying that the crystallization can be carried out in suitable solvents or solvent systems and summarily showing in some examples that the product coming from the reaction can be crystallized from the 7:3 mixture of ethyl alcohol/water and can be dried both under atmospheric pressure and under vacuum without saying in any way neither the experimental conditions of crystallization and drying, nor any distinctive crystallographic characteristic of the obtained product.
  • The presence of different polymorphs had not been just noticed and therefore the experimental conditions described in both patents had been developed with the goal to get a homogeneous product having a suitable purity from the chemical point of view, apart from the crystallographic aspects of the product itself.
  • It has now be found, unexpectedly, that some polymorphous forms exist whose formation, in addition to the solvent, depends on the conditions of time and temperature at which both the crystallization and the drying are carried out.
  • These orderly polymorphous forms will be, later on, conventionally identified as rifaximin δ (FIG. 1) and rifaximin ε (FIG. 2) on the basis of their respective specific diffractograms reported in the present application.
  • The polymorphous forms of the rifaximin have been characterized through the technique of the powder X-ray diffraction.
  • The identification and characterization of these polymorphous forms and, contemporarily, the definition of the experimental conditions for obtaining them is very important for a compound endowed with pharmacological activity which, like the rifaximin, is marketed as medicinal preparation, both for human and veterinary use. In fact it is known that the polymorphism of a compound that can be used as active principle contained in a medicinal preparation can influence the pharmaco-toxicologic properties of the drug. Different polymorphous forms of an active principle administered as drug under oral or topical form can modify many properties thereof like bioavailability, solubility, stability, color, compressibility, flowability and workability with consequent modification of the profiles of toxicological safety, clinical effectiveness and productive efficiency.
  • What above mentioned is confirmed with authority by the fact that the authorities that regulate the grant of the authorization for the admission of the drugs on the market require that the manufacturing methods of the active principles are standardized and controlled in such a way that they give homogeneous and sound results in terms of polymorphism of the production batches (CPMP/QWP/96, 2003—Note for Guidance on Chemistry of new Active Substance; CPMP/ICH/367/96—Note for guidance specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances; Date for coming into operation: May 2000).
  • The need of the above-mentioned standardization has further been strengthened just in the field of the rifamycin antibiotics from Henwood S. Q., de Villiers M. M., Liebenberg W. and Lotter A. P., Drug Development and Industrial Pharmacy, 26 (4), 403-408, (2000), who have ascertained that different production batches of the rifampicin (INN) made from different manufacturers differ among them because they show different polymorphous characteristics, and as a consequence they show different profiles of dissolution together with consequent alteration of the respective pharmacological properties.
  • By applying the processes of crystallization and drying generically disclosed in the previous patents IT 1154655 and EP 0161534 it has been found that under some experimental conditions the poorly crystalline form of the rifaximin is obtained while under other experimental conditions the other crystalline polymorphous forms of the rifaximin are obtained. Moreover it has been found that some parameters, absolutely not disclosed in the above-mentioned patents, like for instance the conditions of preservation and the relative humidity of the ambient, have the surprising effect to determine the form of the polymorph.
  • The polymorphous forms of the rifaximin object of the present patent application were never seen or hypothesized, while thinking that a sole homogeneous product would always have been obtained whichever method would have been chosen within the range of the described conditions, irrespective of the conditions used for crystallizing, drying and preserving.
  • It has now been found that the formation of the δ and ε forms depends on the presence of water within the crystallization solvent, on the temperature at which the product is crystallized and on the amount of water present into the product at the end of the drying phase.
  • The form δ and the form ε of the rifaximin have then been synthesized and they are the object of the invention.
  • In particular the form δ is characterized by the residual content of water in the dried solid material in the range from 2.5% and 6% (w/w), more preferably from 3% and 4.5%, while the form ε is the result of a polymorphic transition under controlled temperature moving from the form δ.
  • These results have a remarkable importance as they determine the conditions of industrial manufacturing of some steps of working which could not be considered critical for the determination of the polymorphism of a product, like for instance the maintaining to a crystallized product a quantity of water in a stringent range of values, or the process of drying the final product, in which a form, namely form δ, has to be obtained prior to continuing the drying to obtain the form δ, or the conditions of preservation of the end product, or the characteristics of the container in which the product is preserved.
  • Rifaximin exerts its broad antibacterial activity in the gastrointestinal tract against localized gastrointestinal bacteria that cause infectious diarrhea including anaerobic strains. It has been reported that rifaximin is characterized by a negligible systemic absorption, due to its chemical and physical characteristics (Descombe J. J. et al. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin. Pharmacol. Res., 14 (2), 51-56, (1994))
  • Now we have found that it is possible on the basis of the two identified polymorphic forms of rifaximin to modulate its level of systemic adsorption, and this is part of the present invention, by administering distinct polymorphous forms of rifaximin, namely rifaximin δ and rifaximin ε. It is possible to have a difference in the adsorption of almost 100 folds in the range from 0.001 to 0.3 μg/ml in blood.
  • The evidenced difference in the bioavailability is important because it can differentiate the pharmacological and toxicological behavior of the two polymorphous of rifaximins δ and ε.
  • As a matter of fact, rifaximin ε is negligibly absorbed through the oral route while rifaximin δ shows a mild absorption.
  • Rifaximin ε is practically not absorbed, might act only through a topical action, including the case of the gastro-intestinal tract, with the advantage of very low toxicity.
  • On the other way, rifaximin δ, which is mildly absorbed, can find an advantageous use against systemic microorganisms, able to hide themselves and to partially elude the action of the topic antibiotics.
  • In respect of possible adverse events coupled to the therapeutic use of rifaximin of particular relevance is the induction of bacterial resistance to the antibiotics. Generally speaking, it is always possible in the therapeutic practice with antibiotics to induce bacterial resistance to the same or to other antibiotic through selection of resistant strains.
  • In case of rifaximin, this aspect is particularly relevant, since rifaximin belongs to the rifamycin family, a member of which, the rifampicin, is largely used in tuberculosis therapy. The current short course treatment of tuberculosis is a combination therapy involving four active pharmaceutical ingredients: rifampicin, isoniazid, ethambutol and pyrazinamide and among them rifampicin plays a pivotal role. Therefore, any drug which jeopardized the efficacy of the therapy by selecting for resistance to rifampicin would be harmful. (Kremer L. et al. “Re-emergence of tuberculosis: strategies and treatment”, Expert Opin. Investig. Drugs, 11 (2), 153-157, (2002)).
  • In principle, looking at the structural similarity between rifaximin and rifampicin, it might be possible by using rifaximin to select resistant strains of M. tuberculosis and to induce cross-resistance to rifampicin. In order to avoid this negative event it is crucial to have a control of quantity of rifaximin systemically absorbed.
  • Under this point of view, the difference found in the systemic absorption of the δ and ε forms of the rifaximin is significant, since also at sub-inhibitory concentration of rifaximin, such as in the range of from 0.1 to 1 μg/ml, selection of resistant mutants has been demonstrated to be possible (Marchese A. et al. In vitro activity of rifaximin, metronidazole and vancomycin against clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy, 46(4), 253-266, (2000)).
  • According to what above said, the importance of the present invention, which has led to the knowledge of the existence of the above mentioned rifaximin polymorphous forms and to various industrial routes for manufacturing pure single forms having different pharmacological properties, is clearly strengthened.
  • The above-mentioned δ and ε forms can be advantageously used as pure and homogeneous products in the manufacture of medicinal preparations containing rifaximin.
  • As already said, the process for manufacturing rifaximin from rifamycin O disclosed and claimed in EP 0161534 is deficient from the point of view of the purification and identification of the product obtained; it shows some limits also from the synthetic point of view as regards, for instance, the very long reaction times, from 16 to 72 hours, very little suitable for an industrial use and moreover because it does not provide for the in situ reduction of the rifaximin oxidized that may be formed within the reaction mixture.
  • Therefore, a further object of the present invention is an improved process for the industrial manufacturing of the δ and ε forms of the rifaximin, herein claimed as products and usable as defined and homogeneous active principles in the manufacture of the medicinal preparations containing such active principle.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a powder X-ray diffractogram of rifaximin δ.
  • FIG. 2 is a powder X-ray diffractogram of rifaximin ε.
  • DESCRIPTION OF THE INVENTION
  • As already said, the form δ and the form c of the antibiotic known as rifaximin (INN), processes for their production and the use thereof in the manufacture of medicinal preparations for oral or topical route, are object of the present invention.
  • A process object of the present invention comprises reacting one molar equivalent of rifamycin O with an excess of 2-amino-4-methylpyridine, preferably from 2.0 to 3.5 molar equivalents, in a solvent mixture made of water and ethyl alcohol in volumetric ratios between 1:1 and 2:1, for a period of time between 2 and 8 hours at a temperature between 40° C. and 60° C.
  • At the end of the reaction the reaction mass is cooled to room temperature and is added with a solution of ascorbic acid in a mixture of water, ethyl alcohol and aqueous concentrated hydrochloric acid, under strong stirring, in order to reduce the small amount of oxidized rifaximin that forms during the reaction and finally the pH is brought to about 2.0 by means of a further addition of concentrated aqueous solution of hydrochloric acid, in order to better remove the excess of 2-amino-4-methylpyridine used in the reaction. The suspension is filtered and the obtained solid is washed with the same solvent mixture water/ethyl alcohol used in the reaction. Such semi finished product is called “raw rifaximin”.
  • The raw rifaximin can be directly submitted to the subsequent step of purification. Alternately, in case long times of preservation of the semi finished product are expected, the raw rifaximin can be dried under vacuum at a temperature lower than 65° C. for a period of time between 6 and 24 hours, such semi finished product is called “dried raw rifaximin”.
  • The so obtained raw rifaximin and/or dried raw rifaximin are purified by dissolving them in ethyl alcohol at a temperature between 45° C. and 65° C. and by crystallizing them by addition of water, preferably in weight amounts between 15% and 70% in respect of the amount by weight of the ethyl alcohol used for the dissolution, and by keeping the obtained suspension at a temperature between 50° C. and 0° C. under stirring during a period of time between 4 and 36 hours.
  • The suspension is filtered and the obtained solid is washed with water and dried under vacuum or under normal pressure, with or without a drying agent, at a temperature between the room temperature and 105° C. for a period of time between 2 and 72 hours.
  • The achievement of the δ and ε forms depends on the conditions chosen for the crystallization. In particular, the composition of the solvent mixture from which the crystallization is carried out, the temperature at which the reaction mixture is kept after the crystallization and the period of time at which that temperature is kept, have proven to be critical.
  • More precisely, the δ and ε rifaximins are obtained when the temperature is first brought to a value between 28° C. and 32° C. in order to cause the beginning of the crystallization, then the suspension is brought to a temperature between 40° C. and 50° C. and kept at this value for a period of time between 6 and 24 hours, then the suspension is quickly cooled to 0° C., in a period of time between 15 minutes and one hour, is filtered, the solid is washed with water and then is dried.
  • The step of drying has an important part in obtaining the δ and ε polymorphous forms of the rifaximin and has to be checked by means of a suitable method fit for the water dosage, like for instance the Karl Fisher method, in order to check the amount of remaining water present in the product under drying.
  • The obtaining of the rifaximin δ during the drying in fact depends on the end remaining amount of water which should be comprised from 2.5% (w/w) and 6% (w/w), more preferably between—3% and 4.5%, and not from the experimental conditions of pressure and temperature at which this critical limit of water percent is achieved.
  • In order to obtain the poorly adsorbed ε form it has to start from the δ form and it has to be continued the drying under vacuum or at atmospheric pressure, at room temperature or at high temperatures, in the presence or in the absence of drying agents, provided that the drying is prolonged for the time necessary so that the conversion in form E is achieved.
  • Both the forms δ and ε of the rifaximin are hygroscopic, they absorb water in a reversible way during the time in the presence of suitable conditions of pressure and humidity in the ambient and are susceptible of transformation to other forms.
  • The transitions from one form to another result to be very important in the ambit of the invention, because they can be an alternative manufacturing method for obtaining the form desired for the production of the medicinal preparations. Therefore, the process that allows to turn the rifaximin δ into rifaximin ε in a valid industrial manner is important part of the invention.
  • The process concerning the transformation of the rifaximin δ into rifaximin E comprises drying the rifaximin δ under vacuum or at atmospheric pressure, at room temperature or at high temperatures, in the presence or in the absence of drying agents, and keeping it for a period of time until the conversion is obtained, usually between 6 and 36 hours.
  • From what above said, it results that during the phase of preservation of the product a particular care has to be taken so that the ambient conditions do not change the water content of the product, by preserving the product in ambient having controlled humidity or in closed containers that do not allow in a significant way the exchange of water with the exterior ambient.
  • The polymorph called rifaximin δ is characterized from a content of water in the range between 2.5% and 6%, preferably between 3.0% and 4.5% and from a powder X-ray diffractogram (reported in FIG. 1) which shows peaks at the values of the diffraction angles 2θ of 5.70°±0.2, 6.7°±0.2, 7.1°±0.2, 8.0°±0.2, 8.7°±0.2, 10.4°±0.2, 10.8°±0.2, 11.3°±0.2, 12.1°±0.2, 17.0°±0.2, 17.3°±0.2, 17.5°±0.2, 18.5°±0.2, 18.8°±0.2, 19.1°±0.2, 21.0°±0.2, 21.5°±0.2. The polymorph called rifaximin E is characterized from a powder X-ray diffractogram (reported in FIG. 2) which shows peaks at the values of the diffraction angles 2θ of 7.0°±0.2, 7.3°±0.2, 8.2°±0.2, 8.7°±0.2, 10.3°±0.2, 11.1°±0.2, 11.7°±0.2, 12.4°±0.2, 14.5°±0.2, 16.3°±0.2, 17.2°±0.2, 18.0°±0.2, 19.4°±0.2.
  • The diffractograms have been carried out by means of the Philips X'Pert instrument endowed with Bragg-Brentano geometry and under the following working conditions:
  • X-ray tube: Copper
  • Radiation used: K (α1), K (α2)
  • Tension and current of the generator: KV 40, mA 40
  • Monochromator: Graphite
  • Step size: 0.02
  • Time per step: 1.25 seconds
  • Starting and final angular 2θ value: 3.0°/30.0°
  • The evaluation of the content of water present in the analysed samples has always been carried out by means of the Karl Fisher method.
  • Rifaximin δ and rifaximin ε differ each from other also because they show significant differences as regards bioavailability.
  • A bioavailability study of the two polymorphs has been carried out on
  • Beagle female dogs, treated them by oral route with a dose of 100 mg/kg in capsule of one of the polymorphs, collecting blood samples from the jugular vein of each animal before each dosing and 1, 2, 4, 6, 8 and 24 hours after each dosing, transferring the samples into tubes containing heparin and separating the plasma by centrifugation.
  • The plasma has been assayed for rifaximin on the validated LC-MS/MS method and the maximum observed plasma concentration (Cmax), the time to reach the Cmax (Tmax), and the area under the concentration-time curve (AUC) have been calculated.
  • The experimental data reported in the following table 1 clearly show that rifaximin E is negligibly absorbed, while rifaximin δ is absorbed at a value (Cmax=0.308 μg/ml) comprised in the range of from 0.1 to 1.0 μg/ml.
  • TABLE 1
    Pharmacokinetic parameters for rifaximin polymorphs following single
    oral administration of 100 mg/kg by capsules to female dogs
    Cmax AUC 0-24 ng ·
    ng/ml Tmax h h/ml
    Mean Mean Mean
    Polymorph δ 308.31 2 801
    Polymorph ε 6.86 4 42
  • The above experimental results further point out the differences existing among the two rifaximin polymorphs.
  • The forms δ and ε can be advantageously used in the production of medicinal preparations having antibiotic activity, containing rifaximin, for both oral and topical use. The medicinal preparations for oral use contain the rifaximin δ and a together with the usual excipients as diluting agents like mannitol, lactose and sorbitol; binding agents like starches, gelatins, sugars, cellulose derivatives, natural gums and polyvinylpyrrolidone; lubricating agents like talc, stearates, hydrogenated vegetable oils, polyethylenglycol and colloidal silicon dioxide: disintegrating agents like starches, celluloses, alginates, gums and reticulated polymers; coloring, flavoring and sweetening agents.
  • All the solid preparations administrable by oral route can be used in the ambit of the present invention, for instance coated and uncoated tablets, capsules made of soft and hard gelatin, sugar-coated pills, lozenges, wafer sheets, pellets and powders in sealed packets.
  • The medicinal preparations for topical use contain the rifaximin δ and ε together with the usual excipients like white petrolatum, white wax, lanoline and derivatives thereof, stearylic alcohol, propylenglycol, sodium lauryl sulfate, ethers of the fatty polyoxyethylene alcohols, esters of the fatty polyoxyethylene acids, sorbitan monostearate, glyceryl monostearate, propylene glycol monostearate, polyethylene glycols, methylcellulose, hydroxymethylpropylcellulose, sodium carboxymethylcellulose, colloidal aluminum and magnesium silicate, sodium alginate.
  • All the topical preparations can be used in the ambit of the present invention, for instance the ointments, the pomades, the creams, the gels and the lotions.
  • The invention is herein below illustrated from some examples that do not have to be taken as a limitation of the invention: from what described results in fact evident that the forms δ and ε can be obtained by suitably combining between them the above mentioned conditions of crystallization and drying.
  • Example 1
  • Preparation of Raw Rifaximin and of Dried Raw Rifaximin
  • In a three-necked flask equipped with mechanic stirrer, thermometer and reflux condenser, 120 ml of demineralized water, 96 ml of ethyl alcohol, 63.5 g of rifamycin O and 27.2 g of 2-amino-4-methylpyridine are loaded in succession at room temperature. After the loading, the mass is heated at 47±3° C., is kept under stirring at this temperature for 5 hours, then is cooled to 2°±3° C. and, during 30 minutes, is added with a mixture, prepared separately, made of 9 ml of demineralized water, 12.6 ml of ethyl alcohol, 1.68 g of ascorbic acid and 9.28 g of aqueous concentrated hydrochloric acid. At the end of the addition, the mass is kept under stirring for 30 minutes at an interior temperature of 2°±−3° C. and then, at the same temperature, 7.72 g of concentrated hydrochloric acid are dripped until a pH equal to 2.0.
  • At the end of the addition, the mass is kept under stirring, always at an interior temperature equal to 20° C., for 30 minutes, then the precipitate is filtered and washed by means of a mixture made of 32 ml of demineralized water and of 25 ml of ethyl alcohol. The so obtained “raw rifaximin” (89.2 g) is dried under vacuum at room temperature for 12 hours obtaining 64.4 g of “dried raw rifaximin” which shows a water content equal to 5.6%. The product by further drying under vacuum until the weight of 62.2 g of dried raw rifaximin having a water content equal to 3.3%, whose diffractogram corresponds to the polymorphous form δ characterized from a powder X-ray diffractogram showing peaks at values of angles 2θ of 5.7°±0.2, 6.7°±0.2, 7.1°±0.2, 8.0°:0.2, 8.7°±0.2, 10.4°±0.2, 10.8°±0.2, 11.3°±0.2, 12.1°±0.2, 17.0°±0.2, 17.3°±0.2, 17.5°±0.2, 18.5°±0.2, 18.8°±0.2, 19.1°±0.2, 21.0°±0.2, 21.5°±0.2. The product is hygroscopic.
  • Example 2
  • Preparation of Rifaximin ε
  • Example 1 is repeated and after having obtained the 6 form, the solid powder is further dried under vacuum for 24 hours at the temperature of 65° C. The product obtained is rifaximin ε characterized from a powder X-ray diffractogram showing peaks at values of angles 2θ of 7.0°±0.2, 7.3°±0.2, 8.2°±0.2, 8.7010.2, 10.3°±0.2, 11.1°±0.2, 11.7°±0.2, 12.4°±0.2, 14.5°±0.2, 16.3°±0.2, 17.2°±0.2, 18.0°±0.2, 19.4°±0.2.
  • Example 3
  • Bioavailability in Dogs By Oral Route
  • Eight pure-bred Beagle females dogs having 20 weeks of age and weighing between 5.0 and 7.5 kg have been divided into two groups of four.
  • The first of these group has been treated with rifaximin δ, the second with rifaximin ε according to the following procedure.
  • To each dog have been administered by the oral route 100 mg/kg of one of the rifaximin polymorphs into gelatin capsules and blood samples of 2 ml each have been collected from the jugular vein of each animal before each dispensing and 1, 2, 4, 6, 8 and 24 hours after the administration.
  • Each sample has been transferred into a tube containing heparin as anticoagulant and has been centrifuged; the plasma has been divided into two aliquots, each of 500 μl, and has been frozen at −20° C.
  • The rifaximin contained in the plasma has been assayed by means of the validated LC-MS/MS method and the following parameters have been calculated according to standard non-compartmental analysis:
  • Cmax=maximum observed plasma concentration of rifaximin in the plasma;
  • Tmax=time at which the Cmax is reached;
  • AUC=area under the concentration-time curve calculated through the linear trapezoidal rule.
  • The results reported in the table 1 clearly show how the rifaximin δ is much more absorbed, more than 40 times, in respect of rifaximin ε, which is practically not absorbed.

Claims (18)

What is claimed is:
1. Rifaximin in polymorphic form δ, wherein the rifaximin polymorphic form δ has x-ray powder diffraction pattern peaks at about 5.7°±0.2, 12.1°±0.2, and 17.0°±0.2 2-θ.
2. The rifaximin in polymorphic form δ of claim 1, wherein the x-ray powder diffraction pattern further comprises a peak at about 11.3°±0.2 2-θ.
3. The rifaximin in polymorphic form δ of claim 1, wherein the x-ray powder diffraction pattern further comprises peaks at about 7.1°±0.2 and 21.5°±0.2 2-θ.
4. The rifaximin in polymorphic form δ of claim 1, wherein the x-ray powder diffraction pattern further comprises peaks at about 6.7°±0.2 and 8.7°±0.2 2-θ.
5. The rifaximin in polymorphic form δ of claim 1, wherein the polymorph has x-ray powder diffraction pattern peaks at about 5.7°±0.2, 6.7°±0.2, 7.1°±0.2, 8.0°±0.2, 8.7°±0.2, 10.4°±0.2, 11.3°±0.2, 12.1°±0.2, 17.0°±0.2, 17.3±0.2, 17.5°±0.2, 18.5°±0.2, 18.8°±0.2, 19.1°±0.2, 21.0°±0.2 and 21.5°±0.2 2-θ.
6. The rifaximin in polymorphic form δ of claim 1, wherein the polymorph 5 has a water content of between 3% and 4.5%.
7. The rifaximin in polymorphic form δ of claim 1, wherein the polymorph 5 has a water content of between 2.5% and 6%.
8. Rifaximin in polymorphic form ε, wherein the rifaximin polymorphic form c has x-ray powder diffraction pattern peaks at about 8.2°±0.2, 12.4°±0.2, and 16.3°±0.2 2-θ.
9. A method of treating bacterial activity in the gastrointestinal tract of a subject, comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of rifaximin δ, thereby reducing the bacterial activity in the gastrointestinal tract, wherein the rifaximin polymorphic form δ has x-ray powder diffraction pattern peaks at about 5.7°±0.2, 12.1°±0.2, and 17.0°±0.2 2-θ.
10. The method of claim 9, wherein the bacterial activity causes infectious diarrhea.
11. The method of claim 9, wherein the bacteria are anaerobic bacteria.
12. The method of claim 9, wherein the pharmaceutical composition is administered orally.
13. The method of claim 9, wherein the bacteria are gastrointestinal bacteria.
14. A method of treating bacterial activity in the gastrointestinal tract of a subject, comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of rifaximin ε, thereby reducing the bacterial activity in the gastrointestinal tract, wherein the rifaximin polymorphic form ε has x-ray powder diffraction pattern peaks at about 8.2°±0.2, 12.4°±0.2, and 16.3°±0.2 2-θ.
15. The method of claim 14, wherein the bacterial activity causes infectious diarrhea.
16. The method of claim 14, wherein the bacteria are anaerobic bacteria.
17. The method of claim 14, wherein the pharmaceutical composition is administered orally.
18. The method of claim 14, wherein the bacteria are gastrointestinal bacteria.
US15/811,536 2005-03-03 2017-11-13 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations Abandoned US20180291032A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US15/811,536 US20180291032A1 (en) 2005-03-03 2017-11-13 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US16/291,900 US10703763B2 (en) 2005-03-03 2019-03-04 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US16/878,511 US20200277301A1 (en) 2005-03-03 2020-05-19 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US17/563,579 US20220119403A1 (en) 2005-03-03 2021-12-28 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
EP05004695.2A EP1698630B1 (en) 2005-03-03 2005-03-03 New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
EP05004695.2 2005-03-03
PCT/EP2006/001755 WO2006094662A1 (en) 2005-03-03 2006-02-27 New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal
US65870207A 2007-10-08 2007-10-08
US13/488,345 US8518949B2 (en) 2005-03-03 2012-06-04 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US13/950,642 US8741904B2 (en) 2005-03-03 2013-07-25 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US14/262,612 US9271968B2 (en) 2005-03-03 2014-04-25 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US14/994,079 US20160362419A1 (en) 2005-03-03 2016-01-12 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US201715481413A 2017-04-06 2017-04-06
US15/811,536 US20180291032A1 (en) 2005-03-03 2017-11-13 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US201715481413A Continuation 2005-03-03 2017-04-06

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/291,900 Continuation US10703763B2 (en) 2005-03-03 2019-03-04 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations

Publications (1)

Publication Number Publication Date
US20180291032A1 true US20180291032A1 (en) 2018-10-11

Family

ID=34934045

Family Applications (9)

Application Number Title Priority Date Filing Date
US11/658,702 Active 2027-09-02 US8193196B2 (en) 2005-03-03 2006-02-27 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US13/488,345 Active US8518949B2 (en) 2005-03-03 2012-06-04 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US13/950,642 Active US8741904B2 (en) 2005-03-03 2013-07-25 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US14/262,612 Active US9271968B2 (en) 2005-03-03 2014-04-25 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US14/994,079 Abandoned US20160362419A1 (en) 2005-03-03 2016-01-12 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US15/811,536 Abandoned US20180291032A1 (en) 2005-03-03 2017-11-13 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US16/291,900 Active US10703763B2 (en) 2005-03-03 2019-03-04 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US16/878,511 Abandoned US20200277301A1 (en) 2005-03-03 2020-05-19 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US17/563,579 Abandoned US20220119403A1 (en) 2005-03-03 2021-12-28 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations

Family Applications Before (5)

Application Number Title Priority Date Filing Date
US11/658,702 Active 2027-09-02 US8193196B2 (en) 2005-03-03 2006-02-27 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US13/488,345 Active US8518949B2 (en) 2005-03-03 2012-06-04 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US13/950,642 Active US8741904B2 (en) 2005-03-03 2013-07-25 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US14/262,612 Active US9271968B2 (en) 2005-03-03 2014-04-25 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US14/994,079 Abandoned US20160362419A1 (en) 2005-03-03 2016-01-12 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations

Family Applications After (3)

Application Number Title Priority Date Filing Date
US16/291,900 Active US10703763B2 (en) 2005-03-03 2019-03-04 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US16/878,511 Abandoned US20200277301A1 (en) 2005-03-03 2020-05-19 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US17/563,579 Abandoned US20220119403A1 (en) 2005-03-03 2021-12-28 Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations

Country Status (28)

Country Link
US (9) US8193196B2 (en)
EP (1) EP1698630B1 (en)
JP (2) JP5737825B2 (en)
KR (1) KR100885755B1 (en)
CN (1) CN1900077B (en)
AU (1) AU2006222312B8 (en)
BR (1) BRPI0608073A8 (en)
CA (1) CA2594789C (en)
DK (1) DK1698630T3 (en)
ES (1) ES2522895T3 (en)
HK (1) HK1096396A1 (en)
HR (1) HRP20070433B1 (en)
IL (1) IL184694A0 (en)
MA (1) MA29345B1 (en)
MD (1) MD4081G2 (en)
ME (1) ME00272B (en)
MX (1) MX2007010742A (en)
NO (1) NO342197B1 (en)
NZ (1) NZ556737A (en)
PL (1) PL1698630T3 (en)
PT (1) PT1698630E (en)
RS (1) RS54570B1 (en)
RU (1) RU2397985C2 (en)
SI (1) SI1698630T1 (en)
TN (1) TNSN07292A1 (en)
UA (1) UA89809C2 (en)
WO (1) WO2006094662A1 (en)
ZA (1) ZA200707397B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10428086B2 (en) 2014-05-12 2019-10-01 Alfasigma S.P.A. Solvated crystal form of rifaximin, production, compositions and uses thereof

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
ITMI20032144A1 (en) 2003-11-07 2005-05-08 Alfa Wassermann Spa REFLEXIMINE POLIMORPHIC FORMS, PROCESSES TO OBTAIN THEM AND
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
PT1698630E (en) 2005-03-03 2014-09-15 Alfa Wassermann Spa New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
ITBO20050123A1 (en) 2005-03-07 2005-06-06 Alfa Wassermann Spa GASTRORESISTIC PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINA
ITMI20061692A1 (en) 2006-09-05 2008-03-06 Alfa Wassermann Spa USE OF POLYOLS TO OBTAIN STYLE POLYMORPHIC FORMS OF RIFAXIMINA
NZ575550A (en) * 2006-09-22 2011-12-22 Cipla Ltd Rifaximin
ITMI20071241A1 (en) * 2007-06-20 2008-12-21 Solmag S P A PROCESS FOR THE PREPARATION OF RIFAXIMINA AMORFA AND RIFAXIMINA AMORPHAS SO OBTAINED
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
CN104650114A (en) 2008-02-25 2015-05-27 萨利克斯药品有限公司 Forms of rifaximin and uses thereof
PL2252148T3 (en) 2008-02-26 2019-09-30 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome
US20110065741A1 (en) 2009-02-26 2011-03-17 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs)
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
SI2294012T1 (en) 2008-05-07 2014-11-28 Salix Pharmaceuticals, Ltd. Administration of a bowel cleanser and an antibiotic for the treatment of bowel disease
EP2327407B1 (en) 2008-09-26 2014-07-09 ASKA Pharmaceutical Co., Ltd. Prophylactic and/or therapeutic agent for functional gastrointestinal disorders
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
CA2739436C (en) 2008-10-02 2019-08-27 Salix Pharmaceuticals, Ltd. Use of rifaximin for treating hepatic encephalopathy
KR20110107806A (en) 2008-12-10 2011-10-04 시플라 리미티드 Rifaximin complexes
WO2011061519A2 (en) 2009-11-23 2011-05-26 Cipla Limited Topical foam composition
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
EP2536282A4 (en) 2010-02-18 2013-07-03 Salix Pharmaceuticals Ltd Methods for treating infection
IT1398550B1 (en) 2010-03-05 2013-03-01 Alfa Wassermann Spa RIFAXIMINA COMPREHENSIVE FORMULATIONS USEFUL TO OBTAIN A PROLONGED EFFECT IN TIME
CN101836959A (en) * 2010-05-20 2010-09-22 山东达因海洋生物制药股份有限公司 Method for preparing almost bitterless rifaximin dry suspension
WO2011156897A2 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
PT2593463T (en) 2010-07-12 2020-09-17 Salix Pharmaceuticals Ltd Formulations of rifaximin and uses thereof
WO2012035544A2 (en) 2010-09-13 2012-03-22 Sequent Scientific Ltd. A novel polymorphic form of rifaximin and process for its preparation
IT1403847B1 (en) 2010-09-22 2013-11-08 Alfa Wassermann Spa PHARMACEUTICAL COMPOSITIONS INCLUDING RIFAXIMINA AND THEIR USE.
PT2672970T (en) 2011-02-11 2018-10-11 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
WO2012150561A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (en) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A POLYMORPHO OF RIFAXIMINA AND PROCESS FOR ITS PREPARATION
WO2013027227A1 (en) * 2011-07-20 2013-02-28 Ind-Swift Laboratories Limited Novel polymorphic form i of rifaximin
ITBO20110461A1 (en) 2011-07-29 2013-01-30 Alfa Wassermann Spa PHARMACEUTICAL COMPOSITIONS INCLUDING RIFAXIMINA, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS.
WO2013067394A1 (en) 2011-11-02 2013-05-10 Salix Pharmaceuticals, Ltd Methods for treating irritable bowel syndrome (ibs) and infections
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (en) 2012-07-06 2014-01-07 Alfa Wassermann Spa COMPOSITIONS INCLUDING RIFAXIMINA AND AMINO ACIDS, RIFAXIMINE CRYSTALS DERIVING FROM SUCH COMPOSITIONS AND THEIR USE.
US9849090B2 (en) 2012-12-12 2017-12-26 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of rifaximin
EA201591267A1 (en) 2013-03-15 2016-03-31 Альфа Вассерманн С.П.А. Rifaximine for use in the treatment of vaginal infections
WO2014140995A2 (en) 2013-03-15 2014-09-18 Alfa Wassermann S.P.A. Method for diagnosing vaginal infections
ES2829285T3 (en) 2013-04-12 2021-05-31 Alfasigma Spa Administration of NSAIDs and related compositions, methods and systems
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
US20150103715A1 (en) * 2013-10-14 2015-04-16 Qualcomm Incorporated Downlink control format indicator
ES2621557T3 (en) * 2014-03-31 2017-07-04 Euticals S.P.A. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations
CA2946101A1 (en) 2014-04-19 2015-10-22 Granules India Limited An improved process for the preparation of rifamycin derivatives
MX2016014329A (en) 2014-05-04 2017-02-23 Salix Pharmaceuticals Inc Ibs microbiota and uses thereof.
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
CA2992945A1 (en) 2015-07-17 2017-01-26 Memorial Sloan-Kettering Cancer Center Combination therapy using pdk1 and pi3k inhibitors
WO2017162725A1 (en) * 2016-03-24 2017-09-28 Sandoz Ag Pharmaceutical composition containing rifaximin alpha & delta
EP3373914B2 (en) 2016-03-24 2022-06-01 Sandoz AG Storage stable composition comprising rifaximin alpha
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
RS63751B1 (en) 2016-09-30 2022-12-30 Salix Pharmaceuticals Inc Solid dispersion forms of rifaximin
CA3013161C (en) 2017-04-26 2020-03-24 Sandoz Ag Oral dosage form comprising rifaximin in form beta
DK3645539T3 (en) 2017-06-26 2021-05-10 Biofer Spa PYRIDO-IMIDAZO-RIFAMYCIN DERIVATIVES AS AN ANTIBACTERIAL
IT201700091912A1 (en) * 2017-08-08 2019-02-08 Biofer Spa New pirido-imidazo rifamicine
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
JP2022548788A (en) 2019-09-24 2022-11-21 バウシュ ヘルス アイルランド リミテッド rifaximin liquid formulation
US20230116647A1 (en) 2020-03-24 2023-04-13 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
AU2021298178A1 (en) 2020-06-26 2023-02-02 Bausch Health Ireland Limited Targeted release rifaximin compositions
US20230398102A1 (en) 2020-10-29 2023-12-14 Bausch Health Ireland Limited Rifaximin liquid formulations for use inthe treatment of sickle cell disease

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2043847A1 (en) 1969-05-30 1971-02-19 Takeda Chemical Industries Ltd
CH571064A5 (en) 1973-03-01 1975-12-31 Archifar Ind Chim Trentino Recovery of rieamycin from broths - by oxidn to an insol form
US4267274A (en) 1973-04-26 1981-05-12 Gruppo Lepetit S.P.A. Streptomyces mediterranei mutant capable of production of rifamycin B
GB1470426A (en) 1974-08-30 1977-04-14 Lepetit Spa Rifamycins
IT1154655B (en) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa IMIDAZO-RIFAMYCIN DERIVATIVES METHODS FOR THEIR PREPARATION AND USE AS AN ANTIBACTERIAL ACTION SUBSTANCE
IT1199374B (en) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa PROCESS FOR THE PREPARATION OF PIRIDO-IMIDAZO-RIFAMICINE
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199413B (en) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa PROCESS FOR THE PREPARATION OF PIRIDO-IMIDAZO-RIFAMICINE
US5356625A (en) 1986-08-28 1994-10-18 Enzacor Properties Limited Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
GB8816620D0 (en) 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
ATE125541T1 (en) 1990-06-29 1995-08-15 Lepetit Spa PURE CRYSTALLINE FORM OF RIFAPENTIN.
IT1253711B (en) 1991-12-17 1995-08-23 Alfa Wassermann Spa VAGINAL PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS
IT1264494B1 (en) 1993-03-23 1996-09-24 Alfa Wassermann Spa USE OF RIFAXIMIN AND FORMULATIONS THAT CONTAIN IT IN THE TREATMENT OF GASTRIC DYSPEPSIES ORIGINATED BY HELICOBACTER
US6271001B1 (en) 1995-03-23 2001-08-07 Bio Polymers Pty. Ltd. Cultured plant cell gums for food, pharmaceutical, cosmetic and industrial applications
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
IT1283911B1 (en) 1996-02-05 1998-05-07 Farmigea Spa VISCOSIZED OPHTHALMIC SOLUTIONS WITH TAMARIND GUM POLYSACCHARIDES
NZ335317A (en) 1996-10-16 2001-02-23 Shaman Pharmaceuticals Inc A proanthocyanidin polymer anti-diarrheal composition formulated as a suppository or as an oral formulation which is protected from stomach acid action
IT1290679B1 (en) 1997-02-14 1998-12-10 Alfa Wassermann Spa USE OF RIFAXIMINE AND OF THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT IN THE TREATMENT OF DIARRHEA FROM CRYPTOSPORIDIOSIS.
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US20030157174A1 (en) 2000-03-23 2003-08-21 Takayuki Tsukuda Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
CA2426393C (en) * 2000-10-31 2012-05-29 Ciba Specialty Chemicals Holding Inc. Crystalline forms of venlafaxine hydrochloride
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2445506C (en) 2001-05-03 2009-04-14 Farmigea S.P.A. Use of sucralfate for the treatment of cervical erosion
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
ATE446096T1 (en) 2002-06-03 2009-11-15 Cac Corp TOPICAL PREPARATIONS FOR THE TREATMENT OF DERMATITIS
CZ13908U1 (en) 2003-10-08 2004-01-05 Cpn Spol. S R.O. Cosmetic preparation containing a high-molecular antioxidant component
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
ITMI20032144A1 (en) * 2003-11-07 2005-05-08 Alfa Wassermann Spa REFLEXIMINE POLIMORPHIC FORMS, PROCESSES TO OBTAIN THEM AND
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20050256118A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US20070281960A1 (en) 2004-07-16 2007-12-06 Amar Lulla Anti-Histaminic Composition
US8003118B2 (en) 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
US20060210483A1 (en) 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US20060210492A1 (en) 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
PT1698630E (en) * 2005-03-03 2014-09-15 Alfa Wassermann Spa New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
ITBO20050123A1 (en) 2005-03-07 2005-06-06 Alfa Wassermann Spa GASTRORESISTIC PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINA
ITBO20050388A1 (en) 2005-06-06 2006-12-07 Alfa Wassermann Spa USEFUL FORMULATION OF MUCOADESIVES IN MEDICAL DEVICES IN PHARMACEUTICAL PREPARATIONS
ITMI20061692A1 (en) 2006-09-05 2008-03-06 Alfa Wassermann Spa USE OF POLYOLS TO OBTAIN STYLE POLYMORPHIC FORMS OF RIFAXIMINA
NZ575550A (en) 2006-09-22 2011-12-22 Cipla Ltd Rifaximin
ITMI20071241A1 (en) 2007-06-20 2008-12-21 Solmag S P A PROCESS FOR THE PREPARATION OF RIFAXIMINA AMORFA AND RIFAXIMINA AMORPHAS SO OBTAINED
SI2011486T1 (en) 2007-07-06 2012-10-30 Lupin Ltd Pharmaceutical compositions of rifaximin
JP5755878B2 (en) 2007-07-06 2015-07-29 ルパン リミテッドLupin Limited Pharmaceutical composition of rifaximin
US8974825B2 (en) 2007-07-06 2015-03-10 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
JP2010259452A (en) * 2007-08-21 2010-11-18 Konica Minolta Medical & Graphic Inc Diagnostic imaging support apparatus and diagnostic imaging support method
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (en) 2007-10-10 2011-01-06 ルピン・リミテッド Pharmaceutical combinations and compositions for treating gastrointestinal disorders
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
CN104650114A (en) 2008-02-25 2015-05-27 萨利克斯药品有限公司 Forms of rifaximin and uses thereof
PL2252148T3 (en) 2008-02-26 2019-09-30 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome
US20110065741A1 (en) 2009-02-26 2011-03-17 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs)
SI2294012T1 (en) 2008-05-07 2014-11-28 Salix Pharmaceuticals, Ltd. Administration of a bowel cleanser and an antibiotic for the treatment of bowel disease
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US20100317681A1 (en) 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
CA2739436C (en) 2008-10-02 2019-08-27 Salix Pharmaceuticals, Ltd. Use of rifaximin for treating hepatic encephalopathy
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
WO2010044093A1 (en) 2008-10-16 2010-04-22 Strides Arcolab Limited Formulations containing rifaximin
KR20110107806A (en) 2008-12-10 2011-10-04 시플라 리미티드 Rifaximin complexes
JP5276505B2 (en) * 2009-04-06 2013-08-28 株式会社ユニバーサルエンターテインメント Game machine
IT1397617B1 (en) 2009-04-20 2013-01-18 Alfa Wassermann Spa NEW FRENCH DERIVATIVES
NZ597080A (en) 2009-06-15 2014-02-28 Salix Pharmaceuticals Ltd Modulation of systemic exposure to rifaximin
NZ598716A (en) 2009-10-26 2014-08-29 Borody Thomas J Novel enteric combination therapy
CA2778981C (en) 2009-10-27 2019-04-02 Lupin Limited Solid dispersion of rifaximin
WO2011061748A1 (en) 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
WO2011061519A2 (en) 2009-11-23 2011-05-26 Cipla Limited Topical foam composition
CN102724961A (en) 2009-11-23 2012-10-10 希普拉有限公司 Topical foam composition
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
CN101773465B (en) 2010-01-19 2012-11-07 南京泛太化工医药研究所 Polymer micelle medicine carrying system using amino acid as stabilizing agent
EP2536282A4 (en) 2010-02-18 2013-07-03 Salix Pharmaceuticals Ltd Methods for treating infection
IT1398550B1 (en) 2010-03-05 2013-03-01 Alfa Wassermann Spa RIFAXIMINA COMPREHENSIVE FORMULATIONS USEFUL TO OBTAIN A PROLONGED EFFECT IN TIME
EP2544660B1 (en) 2010-03-10 2018-06-13 Lupin Limited Rifaximin ready-to-use suspension
TR201810936T4 (en) 2010-04-23 2018-08-27 Industrial Chemicals Group Ltd Detergent composition.
CA2800668A1 (en) 2010-06-03 2011-12-08 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
WO2011156897A2 (en) 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
PT2593463T (en) 2010-07-12 2020-09-17 Salix Pharmaceuticals Ltd Formulations of rifaximin and uses thereof
WO2012035544A2 (en) 2010-09-13 2012-03-22 Sequent Scientific Ltd. A novel polymorphic form of rifaximin and process for its preparation
AU2011303715A1 (en) 2010-09-13 2013-04-04 Cipla Limited Pharmaceutical composition
IT1403847B1 (en) 2010-09-22 2013-11-08 Alfa Wassermann Spa PHARMACEUTICAL COMPOSITIONS INCLUDING RIFAXIMINA AND THEIR USE.
WO2012060675A1 (en) 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Process for the preparation of amorphous rifaximin
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
PT2672970T (en) 2011-02-11 2018-10-11 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
WO2012150561A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110890A1 (en) 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A POLYMORPHO OF RIFAXIMINA AND PROCESS FOR ITS PREPARATION
ITBO20110461A1 (en) 2011-07-29 2013-01-30 Alfa Wassermann Spa PHARMACEUTICAL COMPOSITIONS INCLUDING RIFAXIMINA, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS.
WO2013067394A1 (en) 2011-11-02 2013-05-10 Salix Pharmaceuticals, Ltd Methods for treating irritable bowel syndrome (ibs) and infections
CA2861104A1 (en) 2012-01-25 2013-08-01 Salix Pharmaceuticals, Ltd. Rifaximin derivative and uses thereof
JP2013184902A (en) 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd Rifaximin containing crystal
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (en) 2012-07-06 2014-01-07 Alfa Wassermann Spa COMPOSITIONS INCLUDING RIFAXIMINA AND AMINO ACIDS, RIFAXIMINE CRYSTALS DERIVING FROM SUCH COMPOSITIONS AND THEIR USE.
US9849090B2 (en) 2012-12-12 2017-12-26 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of rifaximin
ES2829285T3 (en) 2013-04-12 2021-05-31 Alfasigma Spa Administration of NSAIDs and related compositions, methods and systems
JP2016526032A (en) 2013-05-17 2016-09-01 サリックス ファーマスーティカルズ,インコーポレーテッド How to use rifaximin in position (POSITION) emission tomography (PET) scans
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
ITMI20131307A1 (en) 2013-08-02 2015-02-02 A M S A Anonima Materie Sint & Affini S P A PROCESS FOR THE PREPARATION OF REFAXIMINA K
ES2621557T3 (en) 2014-03-31 2017-07-04 Euticals S.P.A. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations
CA2946101A1 (en) 2014-04-19 2015-10-22 Granules India Limited An improved process for the preparation of rifamycin derivatives
HUE044748T2 (en) 2014-05-12 2019-11-28 Alfasigma Spa New solvated crystal form of rifaximin, production, compositions and uses thereof
WO2016063289A2 (en) 2014-10-22 2016-04-28 Strides Arcolab Limited Pharmaceutical tablet compositions comprising rifaximin
WO2017021975A1 (en) 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
EP3373914B2 (en) 2016-03-24 2022-06-01 Sandoz AG Storage stable composition comprising rifaximin alpha
WO2017162725A1 (en) 2016-03-24 2017-09-28 Sandoz Ag Pharmaceutical composition containing rifaximin alpha & delta
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
WO2018158646A1 (en) 2017-03-02 2018-09-07 Granules India Limited Rifaximin crystalline form
WO2018178777A1 (en) 2017-03-31 2018-10-04 Granules India Limited Process for the preparation of rifaximin crystalline form
CA3013161C (en) 2017-04-26 2020-03-24 Sandoz Ag Oral dosage form comprising rifaximin in form beta
DK3645539T3 (en) 2017-06-26 2021-05-10 Biofer Spa PYRIDO-IMIDAZO-RIFAMYCIN DERIVATIVES AS AN ANTIBACTERIAL

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10428086B2 (en) 2014-05-12 2019-10-01 Alfasigma S.P.A. Solvated crystal form of rifaximin, production, compositions and uses thereof

Also Published As

Publication number Publication date
MA29345B1 (en) 2008-03-03
NO20074988L (en) 2007-11-30
US20130310410A1 (en) 2013-11-21
TNSN07292A1 (en) 2008-12-31
US20090130201A1 (en) 2009-05-21
AU2006222312A1 (en) 2006-09-14
AU2006222312B2 (en) 2011-11-03
KR100885755B1 (en) 2009-02-26
US20160362419A1 (en) 2016-12-15
MD4081F2 (en) 2010-12-31
JP5737825B2 (en) 2015-06-17
CN1900077B (en) 2012-04-11
MD20070265A (en) 2008-05-31
IL184694A0 (en) 2007-12-03
US9271968B2 (en) 2016-03-01
US20220119403A1 (en) 2022-04-21
US20150073007A1 (en) 2015-03-12
NO342197B1 (en) 2018-04-16
EP1698630A8 (en) 2006-10-25
AU2006222312B8 (en) 2011-11-17
DK1698630T3 (en) 2014-12-08
US20200002350A1 (en) 2020-01-02
PT1698630E (en) 2014-09-15
US8193196B2 (en) 2012-06-05
EP1698630A1 (en) 2006-09-06
CN1900077A (en) 2007-01-24
US8741904B2 (en) 2014-06-03
WO2006094662A1 (en) 2006-09-14
PL1698630T3 (en) 2014-12-31
BRPI0608073A2 (en) 2009-11-03
US20120245355A1 (en) 2012-09-27
ZA200707397B (en) 2009-03-25
US20200277301A1 (en) 2020-09-03
US8518949B2 (en) 2013-08-27
NZ556737A (en) 2011-11-25
UA89809C2 (en) 2010-03-10
BRPI0608073A8 (en) 2017-12-26
MX2007010742A (en) 2007-09-12
MEP34408A (en) 2011-02-10
HK1096396A1 (en) 2007-06-01
CA2594789C (en) 2010-09-14
SI1698630T1 (en) 2015-01-30
RS54570B1 (en) 2016-06-30
HRP20070433A2 (en) 2007-11-30
MD4081G2 (en) 2011-07-31
RS20070364A (en) 2009-01-22
KR20060096242A (en) 2006-09-11
CA2594789A1 (en) 2006-09-14
RU2397985C2 (en) 2010-08-27
ES2522895T3 (en) 2014-11-19
EP1698630B1 (en) 2014-09-03
RU2007136430A (en) 2009-04-10
JP2008531623A (en) 2008-08-14
HRP20070433B1 (en) 2015-02-27
JP2013216710A (en) 2013-10-24
ME00272B (en) 2011-05-10
US10703763B2 (en) 2020-07-07

Similar Documents

Publication Publication Date Title
US20220119403A1 (en) Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US20220127283A1 (en) Polymorphic forms alpha, beta and gamma of rifaximin
CA2538546C (en) Polymorphic forms of rifaximin, processes for their production and use thereof in medicinal preparations
US20120214989A1 (en) Processes for the production of polymorphic forms of rifaximin
US20120258166A1 (en) Rifaximin compositions and method of use

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALFA WASSERMANN S.P.A., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VISCOMI, GIUSEPPE CLAUDIO;CAMPANA, MANUELA;CONFORTINI, DONATELLA;AND OTHERS;REEL/FRAME:045465/0650

Effective date: 20070212

AS Assignment

Owner name: ALFASIGMA S.P.A., ITALY

Free format text: MERGER;ASSIGNOR:ALFA WASSERMANN S.P.A.;REEL/FRAME:046706/0189

Effective date: 20170421

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION